BRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy

Reuters12-09

BRIEF-<a href="https://laohu8.com/S/CGEM">Cullinan Therapeutics</a> Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy

Dec 8 (Reuters) - Cullinan Therapeutics Inc CGEM.O:

CULLINAN THERAPEUTICS INC - PHASE 1 CLN-049 MONOTHERAPY DEMONSTRATES PROMISING EFFICACY

Source text: ID:nGNX7qfNsN

Further company coverage: CGEM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590352635?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590352635","market":"fut","top_or_hot":-1,"title":"BRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Cullinan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>CGEM.O</span>:</p><ul><li><p>CULLINAN THERAPEUTICS INC - PHASE 1 CLN-049 MONOTHERAPY DEMONSTRATES PROMISING EFFICACY</p></li></ul><p>Source text: <span>ID:nGNX7qfNsN</span></p><p>Further company coverage: <span>CGEM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 00:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Cullinan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>CGEM.O</span>:</p><ul><li><p>CULLINAN THERAPEUTICS INC - PHASE 1 CLN-049 MONOTHERAPY DEMONSTRATES PROMISING EFFICACY</p></li></ul><p>Source text: <span>ID:nGNX7qfNsN</span></p><p>Further company coverage: <span>CGEM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10X:1","article_id":"2590352635","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590352635","pubTimestamp":1765210640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising EfficacyDec 8 (Reuters) - Cullinan Therapeutics Inc CGEM.O:CULLINAN THERAPEUTICS INC - PHASE 1 CLN-049 MONOTHERAPY D","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CGEM":"Cullinan Therapeutics"},"translate_title":"简介–Cullinan Therapeutics表示1期CLN-049单药疗法显示出有希望的疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":0.9},"content_text":"BRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising EfficacyDec 8 (Reuters) - Cullinan Therapeutics Inc CGEM.O:CULLINAN THERAPEUTICS INC - PHASE 1 CLN-049 MONOTHERAPY DEMONSTRATES PROMISING EFFICACYSource text: ID:nGNX7qfNsNFurther company coverage: CGEM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590352635","isCrawlerRequest":true}